Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
4 drugs in development
By Therapeutic Area
top 3
R&D Momentum
89/100
Pipeline Velocity
66/100
Trial Completion Rate
72/100
Pipeline Concentration
33/100
Pipeline Freshness
60/100
Strategic Signals
Activity
Last 14 days
Effects of Oxytocin on Social Cognition Training: Relationship to Target Engagement
Starting Technology in At Risk Type 1 Diabetes (STAR-T1D) Study
Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure
Sex-dependent Effects of Cannabis: Assessing Analgesic, Abuse-related and Pharmacokinetic Differences Between Men and Women
Telerehabilitation In The Home After Stroke: A Randomized, Controlled, Assessor-Blind Clinical Trial
Virtual Reality-Reward Training for Anhedonia
Coaching and Leadership in Autism Support Settings
Mental Health and Wellness Pilot Study Among Aging Immigrants and Refugees
Targeted Upstream Prevention (T-UP): Engaging Vulnerable Students in Diabetes Prevention
Medicare Annual Wellness Visit Practice Redesign Toolkit: A Tailored Intervention to Improve Preventive Health Services Use (Phase 2)
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)